在联合国高级别会议迎来一周年之际，我的最后一项担忧是决策者仍然没有批准旨在鼓励开发新药和新诊断方法的市场进入奖励经费。
One last concern that I have on this first anniversary of the UN High-Level Meeting is that policymakers still need to agree on a source of funding for the market-entry rewards intended to encourage the development of new drugs and diagnostics.